Prenetics Authorizes $40 Million Share Repurchase Program

Rhea-AI Summary

Prenetics (NASDAQ: PRE) authorized a $40.0 million share repurchase program over 12 months, bringing total insider and board-backed commitment to $42.75 million. The company reports $164 million in total adjusted liquidity, zero debt, and IM8 guidance of $180–200 million revenue for 2026, targeting adjusted EBITDA profitability by Q4 2027. Management purchased ~$2.75 million of stock in recent post-earnings windows. The program allows open market, negotiated and Rule 10b5-1 purchases and may be modified or suspended at any time.

Positive

• Board authorized a $40.0M share repurchase program
• Management and board commitment totaling $42.75M to company stock
• $164M total adjusted liquidity on a zero-debt basis
• IM8 2026 revenue guidance of $180M–$200M
• Targeting adjusted EBITDA profitability by Q4 2027
• Executives invested ~$2.75M in open-market purchases

Negative

• Implied enterprise value of approximately $89M, signaling low market valuation
• Repurchase program may be modified, suspended, or discontinued at any time

Key Figures

Share repurchase authorization: $40,000,000 Management & Board commitment: $42.75M Total adjusted liquidity: $164M +5 more

8 metrics

Share repurchase authorization $40,000,000 Board-approved buyback over 12-month period

Management & Board commitment $42.75M Total potential capital committed to Prenetics stock

Total adjusted liquidity $164M Liquidity as of March 1, 2026, on a zero-debt basis

IM8 2026 revenue target $180M–$200M Full-year 2026 revenue target range for IM8

Targeted profitability timing Q4 2027 Target for adjusted EBITDA break-even and sustained profitability

Exec purchases Feb 23–27, 2026 $1.3M at ~$17.11 Open-market buys by leadership team in that week

CEO purchase Feb 23–27 $750,000 Portion of that round personally purchased by CEO Danny Yeung

Enterprise value $89M Approximate EV cited relative to IM8 2026 revenue guidance

Market Reality Check

Price: $17.80 Vol: Volume 208,658 versus 20-...

low vol

$17.80 Last Close

Volume Volume 208,658 versus 20-day average of 326,367 suggests trading was below recent activity levels ahead of this news. low

Technical Shares at $15.07 were trading above the 200-day MA of $12.53, but still 34.08% below the 52-week high of $22.86.

Peers on Argus

PRE’s pre-news setup contrasted with mixed peers: BNR up 3.82%, FONR up 0.38%, B...

1 Up 1 Down

PRE’s pre-news setup contrasted with mixed peers: BNR up 3.82%, FONR up 0.38%, BDSX up 2.7%, while MDXH fell 2.65% and XGN fell 8.78%. Momentum scanner showed only one peer (CDNA up 2.40%) moving in the same direction as the target, while BDSX was down 3.34%, pointing to stock-specific drivers rather than a sector-wide move.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Insider share purchases	Positive	-3.5%	Executives bought 76,060 shares for ~$1.301M, lifting cumulative buys to ~$2.75M.
Feb 23	Product launch	Positive	-8.4%	Launch of IM8 Daily Ultimate Essentials PRO with up to 733% greater potency.
Feb 18	Asset sale	Positive	-7.7%	Completed $70M Insighta sale to Tencent, boosting adjusted liquidity to $171.1M.
Feb 18	Earnings results	Positive	-7.7%	Reported $92.4M FY2025 revenue, ~480% YoY, and reiterated IM8 $180–$200M guidance.
Feb 17	Board appointment	Positive	-7.7%	Added longevity expert Dr. Darshan Shah to the board and key committees.

Pattern Detected

Recent positive corporate, product, and balance-sheet news, including liquidity gains and leadership additions, was followed by negative 24-hour price reactions, suggesting a pattern of the stock selling off or not holding gains on good news.

Recent Company History

Over the past several weeks, Prenetics reported multiple constructive developments: record FY2025 results with strong IM8 growth and guidance, a $70M Insighta divestiture that lifted total adjusted liquidity to $171.1M with zero debt, new IM8 product launches, and board strengthening via Dr. Darshan Shah. Executives also disclosed open-market share purchases totaling about $2.75M. Despite this, each of these announcements coincided with negative 24-hour price reactions, providing important context for today’s board-authorized $40M buyback.

Market Pulse Summary

This announcement outlines a board-authorized $40M share repurchase program, layered on top of rough...

Analysis

This announcement outlines a board-authorized $40M share repurchase program, layered on top of roughly $2.75M in recent executive open‑market purchases and supported by $164M in adjusted liquidity with zero debt. It reinforces management’s focus on IM8, which targets $180M–$200M in 2026 revenue and adjusted EBITDA profitability by Q4 2027. In context of prior strong FY2025 results and strategic divestitures, key metrics to watch are IM8 growth, margin trajectory, and actual buyback execution versus authorization.

Key Terms

share repurchase program, adjusted EBITDA, enterprise value, Rule 10b5-1, +3 more

7 terms

share repurchase program financial

"announced that its Board of Directors ... has authorized a share repurchase program of up to $40,000,000"

A share repurchase program is when a company buys back its own shares from the marketplace. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's prospects. For investors, it often suggests that the company believes its stock is undervalued or that it has extra cash to return to shareholders.

adjusted EBITDA financial

"a clear path to Adjusted EBITDA Profitability by Q4 2027"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

enterprise value financial

"Prenetics trades at an enterprise value of approximately $89 million — less than 0.5x"

Enterprise value is the total worth of a company, reflecting what it would cost to buy the entire business. It includes the company's market value plus any debts, minus its cash holdings, offering a comprehensive picture of its true value. Investors use it to compare companies regardless of their capital structures, helping them assess how much they would need to pay to acquire the business.

Rule 10b5-1 regulatory

"authorized the Company to enter into written trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Class A Ordinary Shares financial

"purchase the Company’s Class A Ordinary Shares in accordance with the terms of the plan"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

NSF Certified for Sport medical

"IM8 is built on NSF Certified for Sport, clinically validated nutrition"

NSF Certified for Sport is a third-party safety seal showing a supplement or sports product has been independently tested to be free of banned substances, contaminants and undeclared ingredients, and that it was made under quality controls. For investors, this label matters because it lowers the chance of regulatory action, athlete bans, or recalls and typically boosts consumer trust and sales—think of it as a safety inspection sticker that helps a product sell more reliably in a sensitive market.

trading plan financial

"Under any Rule 10b5-1 trading plan, the Company’s third-party broker"

A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.

AI-generated analysis. Not financial advice.

• Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock 
• Backed by $164 Million in Total Adjusted Liquidity, Zero Debt
• IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027
  
  

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board of Directors (the “Board”) has authorized a share repurchase program of up to $40,000,000 over a 12-month period.

Management Voted With Its Own Capital First

During the week of February 23 to 27, 2026, members of the Prenetics executive leadership team made open market purchases totaling approximately $1.3 million at an average price of approximately $17.11 per share. CEO Danny Yeung personally purchased approximately $750,000 in that round alone.

Combined with approximately $1.45 million in purchases following the prior earnings release in November 2025, Prenetics’ executive team has now invested a cumulative $2.75 million of personal capital into the Company’s stock across two consecutive post-earnings open trading windows.

The Board’s authorization of a $40 million corporate share repurchase program is the institutional expression of the same conviction. Together, that is up to $42.75 million committed to Prenetics stock by the people who know this business best.

Danny Yeung, CEO of Prenetics, commented: “We have spent the past year doing exactly what we said we would do — building IM8 into one of the fastest-growing supplement brands in the world, strengthening our balance sheet, and eliminating complexity. Our $40 million share repurchase program is the natural next step: a direct expression of the Board's view that the current share price does not yet reflect the underlying value and trajectory of this business. With approximately $164 million in total adjusted liquidity, zero debt, and IM8 on a trajectory toward $180 million to $200 million in 2026 revenue, we have more than sufficient capital to fund growth and this buyback through to profitability — which we are targeting at adjusted EBITDA level by Q4 2027 on the strength of IM8's unit economics. Our executive team has already invested approximately $2.75 million of personal capital in Prenetics stock across recent post-earnings trading windows. This share repurchase program reinforces that same conviction at the institutional level. When you have the capital, the runway, and the business momentum — buying back your own stock is simply the right thing to do for shareholders. That leaves a straightforward decision: hold excess cash at negligible real yield, reinvest it into a business already funded through its profitability horizon, or return it to shareholders by buying stock that management believes is materially undervalued. The Board chose the third option. At current prices, Prenetics trades at an enterprise value of approximately $89 million — less than 0.5x IM8's 2026 revenue guidance of $180 million to $200 million. Stripping out the Company's approximately $164 million in total adjusted liquidity, the market is effectively ascribing near-zero value to a business targeting $180 million to 200 million in revenue this year and adjusted EBITDA profitability by Q4 2027.”

Capital Strength Underpins the Program

During 2025 and into early 2026, Prenetics completed three strategic divestitures — each designed to concentrate the Company's capital and operating focus on its highest-growth, highest-margin business in IM8:

DIVESTITURE	PROCEEDS	BUYER
ACT Genomics	Up to ~$72M cash (~$46M gross to Company)	Delta Electronics
Europa Distribution Business	Up to $13M (all-stock consideration)	Strategic acquirer
35% equity stake in Insighta	$70M cash	Tencent

The result: total adjusted liquidity¹ of approximately $164 million as of March 1, 2026, on a zero-debt basis.

The Capital Allocation Case

With approximately $164 million in total adjusted liquidity and zero debt as of March 1, 2026, Prenetics is not running a capital return program because it has run out of better options. It is running one because the numbers make it the most disciplined choice available.

IM8’s unit economics are strong and improving. The business is on a clear path to profitability, with the Company targeting break-even and sustained profitability in adjusted EBITDA terms by Q4 2027. The Company has more than sufficient capital to fund IM8’s growth through profitability trajectory without deploying the full liquidity on its balance sheet today.

That leaves a straightforward decision: hold excess cash at negligible real yield, reinvest it into a business already funded through its profitability horizon, or return it to shareholders by buying stock that management believes is materially undervalued. The Board chose the third option.

The Asset the Board Is Buying: IM8

Prenetics has spent three years making hard choices — divesting, simplifying, concentrating. Every decision pointed to the same destination: IM8. Co-founded with David Beckham, championed by World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, IM8 is built on NSF Certified for Sport, clinically validated nutrition — and it is the business the Board is backing with up to $40 million.

Program Structure

The Board also authorized the Company to enter into written trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Under any Rule 10b5-1 trading plan, the Company’s third-party broker, subject to Securities and Exchange Commission regulations regarding certain price, market, volume and timing constraints, would have authority to purchase the Company’s Class A Ordinary Shares in accordance with the terms of the plan. Under the share repurchase program, the Company is authorized to repurchase its outstanding Class A Ordinary Shares through open market purchases, privately negotiated transactions, block purchases, or otherwise in accordance with applicable U.S. federal securities laws. The Company cannot predict when, or if, it will repurchase any Class A Ordinary Shares as such share repurchase program will depend on a number of factors, including constraints specified in any Rule 10b5-1 trading plan, price, general business and market conditions, and alternative investment opportunities. The share repurchase program may be modified, suspended or discontinued at any time without prior notice. The share repurchase program does not obligate the Company to acquire any specific number or dollar amount of shares and may be suspended or discontinued at any time.

About Prenetics

Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company’s flagship consumer brand, IM8, co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 30 countries worldwide.

About IM8

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.

Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: future alpha-generating activities involving the Company’s digital asset holdings could expose it to additional risks; the Company’s purchase of digital asset subjects it to risks related to extreme volatility and speculative nature of digital asset; the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; and its ability to identify and execute on M&A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

________________________________
¹ Adjusted liquidity is a non-IFRS financial measure, comprising: cash and cash equivalents of $93.0 million, financial assets at fair value through profit or loss (primarily comprising of fixed income funds) of approximately $29.3 million based on the most recent available valuation and subject to finalization as part of the ongoing annual audit, digital asset holdings valued at approximately $34.2 million, and portions of gross proceeds of the ACT Genomics sale and Insighta sale transactions held in escrow pending fulfillment of customary release conditions of $6.3 million and $1.0 million, respectively. Our total adjusted liquidity decreased from approximately $171 million as of February 15, 2026 to approximately $164 million as of March 1, 2026 on account of expenses used to support inventory growth and marketing costs on advertising services.

FAQ

What size share repurchase did Prenetics (PRE) authorize on March 6, 2026?

Prenetics authorized a $40 million share repurchase program over a 12-month period. According to the company, the program permits open-market, negotiated and Rule 10b5-1 purchases and may be modified or suspended depending on market and business conditions.

How much total capital have Prenetics insiders and the Board committed to PRE stock?

Insiders and the Board have committed up to $42.75 million to Prenetics stock. According to the company, this includes $40 million authorized by the Board plus approximately $2.75 million of recent executive open-market purchases.

What is Prenetics' reported liquidity and debt position as of March 1, 2026?

Prenetics reported approximately $164 million in total adjusted liquidity and zero debt as of March 1, 2026. According to the company, this liquidity follows strategic divestitures completed in 2025 and early 2026.

What revenue and profitability targets did Prenetics give for IM8 in 2026 and beyond?

Prenetics guided IM8 to $180–$200 million revenue for 2026 and is targeting adjusted EBITDA profitability by Q4 2027. According to the company, IM8’s unit economics underpin the path to profitability.

Which divestitures contributed to Prenetics’ adjusted liquidity used to support the buyback?

Divestitures include ACT Genomics (up to ~$72M proceeds, ~ $46M gross to company), Europa distribution (up to $13M all-stock), and a 35% Insighta stake for $70M cash. According to the company, these transactions produced the cited adjusted liquidity.

Will the Prenetics (PRE) repurchase program guarantee a specific number of shares will be bought?

No, the repurchase program does not obligate purchases of any specific number or dollar amount of shares. According to the company, actual repurchases will depend on price, market conditions, and available alternative investments.

How does Prenetics justify the buyback given its 2026 growth plans for IM8?

Prenetics says the buyback is the most disciplined capital allocation given $164M liquidity and IM8’s growth trajectory. According to the company, returning capital now reflects management’s view the shares are materially undervalued relative to IM8’s outlook.